May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Safety of Infliximab on Retinal Cells
Author Affiliations & Notes
  • F. Giansanti
    University of Florence, Florence, Italy
    Eye Clinic,
  • L. Papucci
    University of Florence, Florence, Italy
    Department of Experimental Pathology and Oncology,
  • L. Vannozzi
    University of Florence, Florence, Italy
    Eye Clinic,
  • S. Capaccioli
    University of Florence, Florence, Italy
    Department of Experimental Pathology and Oncology,
  • E. Rapizzi
    University of Florence, Florence, Italy
    Eye Clinic,
  • E. Witort
    University of Florence, Florence, Italy
    Department of Experimental Pathology and Oncology,
  • U. Menchini
    University of Florence, Florence, Italy
    Eye Clinic,
  • Footnotes
    Commercial Relationships  F. Giansanti, None; L. Papucci, None; L. Vannozzi, None; S. Capaccioli, None; E. Rapizzi, None; E. Witort, None; U. Menchini, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5623. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Giansanti, L. Papucci, L. Vannozzi, S. Capaccioli, E. Rapizzi, E. Witort, U. Menchini; Safety of Infliximab on Retinal Cells. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5623. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the cytotoxic properties of infliximab on different ocular cells.

Methods: : Cell culture: ARPE-19 (RPE) cells were maintained in a mixture of Dulbecco’s Modified Eagle’s Medium and Ham’s F12 with 2,5 mM L-glutamine and supplemented with 10% fetal bovine serum in humidified atmosphere of 5% CO2 at 37°C. RGC-5 cells were maintained in Dulbecco’s Modified Eagle’s Medium with 2,5 mM L-glutamine and supplemented with 10% fetal bovine serum in humidified atmosphere of 5% CO2 at 37°C. This cell line was kindly provided by Prof. Neeraj Agarwal, University of North Texas Health Sciences Center - Texas, USA. Treatments: Infliximab (0.1-0.3-1-3-6 mg/ml) diluted in culture medium was added to each cells maintaned in 6-well cell culture plates. Cells were harvested and assayed for apoptosis induction 24-48-72 hours after treatment. Western Blot analysis of Caspase 3 activity:The assays were performed according to standard conditions. The cells were lysed and proteins extracted in Ripa buffer. The protein lysates were obtained by centrifugation and then were analyzed by 12% SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membrane in a Trans-blot apparatus at 100 V for 90 min. The blots were probed with mouse monoclonal anti-Caspase-3 antibody. A mouse monoclonal anti-alpha-Tubulin antibody was used as a protein loading control.

Results: : No apoptotic effect of infliximab at any of the concentrations tested was observed in RPE and RGC-5 cells. In fact, the pro-caspase 3 level were not affected by any of the infliximab concentration tested at any of the time points analysed.

Conclusions: : The experimental findings support the safety of the infliximab at the concentrations and in the conditions tested.

Keywords: retina • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×